Target HLS Customers AstraZeneca & GlaxoSmithKline

ALL ALERTS

EXPERIMENTATION

COMPANION

FOOD-AGRICULTURE

WILD

ENTERTAINMENT

FASHION

HLS FILES › Target HLS Customers AstraZeneca & GlaxoSmithKline

THIS ALERT IS CLOSED. It is archived for research purposes or use as letter-writing example.

AstraZeneca & GlaxoSmithKline, Targets
2013: Customers are key to H-L-S survival. Pharma giants AstraZeneca and GlaxoSmithKline still make shac.net’s target list, with AZ dubbed a Priority Target, since we posted the alert below. Check Kinship Circle Animal Experimentation Alerts for HLS TARGETS with updated contact information.

CLICK HERE FOR NEW ALERT:
TARGET ASTRAZENECA - H.L.S CUSTOMER, BEAGLE KILLER

UPDATE: Pressure On Customers, Financiers, Suppliers = HLS Revenue Loss

2009: Revenue continues to fall for Huntingdon_Life_Sciences, a huge contract animal research lab and subject of 7 investigations over 12 years. H-L-S has multiple breaches of the U.S. Animal Welfare Act, staff arrests on animal cruelty charges, over 520 infringements of Good Laboratory Practice in England, and a 50,000-dollar payoff to the U.S. Agriculture Department for misstated records and animal welfare violations.

Over 12 months H.L.S loses two major customers and share prices plummet by 75 percent, from just under 40 to around 8 dollars, due in part to global campaigns against H-L-S shareholders and customers. H_L_S also loses their top 5 shareholders in 4 months: Barclays, Bank of New York, Mellon and Highbridge Capital. Due to their share price crash, Andrew Baker, Chairman and CEO, even proposes buying out remaining shares at a fixed price of $8.50, to sell to the new Lion Holdings, Inc. As a result, shareholders have filed 2 lawsuits against H.L_S.

H_L_S-L.S.R is still $72 million in debt and published accounts show a revenue decline of 24 percent. No directors took bonuses last year. Brian Cass cut jobs at UK labs and has said the future looks uncertain. With money debts due by 2011, the floundering lab has yet to secure a loan. Ultimately, H-L_S needs $60 million to pay off debts, but risks bankruptcy if they lose another customer.

INFO ABOUT H-L-S & CAMPAIGNS TO CLOSE THE LAB

COMPANIES THAT DUMPED H_L_S FROM 2008 TO 2005

9/9/08 - Global pharmaceutical giant Merck KGaA has no plans to be a customer in the future.

7/30/08 - Raymond James-Eagle Asset Management and Old Mutual (Acadian Asset Management) sell off more than 1.5 million H.L.S-L.S.R shares in 1 month. Once investors learn the lab that kills an average 500 animals daily in experiments only reliable 5-25 percent of the time some disassociate completely.

4/08 - We shall not involve ourselves in the transportation of animals worldwide for testing purposes, as an ethical policy, Pakistan International Airways, Salah Uddin, Director. PIA had been involved in beagle transport for research at HLS.

4/9/08 - I can confirm that neither Yorpower, Power Plant Services nor our sister company Techknol Power Generation perform any work on behalf of Huntingdon_Life_Sciences and the current management have no plans for future dealings with them. YorPower, Guy Phoenix, Director.

12/20/07 - Transamerica Investment, Frontier Capital, SAC Capital, AXA, Wachovia, Alternative Investment Partners and Rathbone Brothers join customers, suppliers, and financiers worldwide that severed ties after learning about habitual falsification of data and animal cruelty.

11/20/07 - Wachovia sells all shares in H.L.S-L.S.R.I, a research lab cited for animal cruelty, with documentation of technicians who kill dogs by flooding lungs with toxic materials meant for the animals’ stomachs. In one video clip, a lab tech repeatedly punches a screaming 4-month old beagle in the face. During a supposedly post-mortem dissection, a tech slices into the chest of a convulsing monkey.

10/1/0 - Paul Moravek, owner-vice president of Moravek Biochemicals, a radioactive chemical supplier to Huntingdon, states his company will cease business with the lab.

9/20/07 - BNP Paribas, largest shareholder, sells all shares in H-L-S.

2/7/07 - Customer Surface Logix issues a statement that they'll never again work with H-L- S, after receiving hundreds of emails, calls and letters from animal advocates.

4/26/06 - H-L-S is dropped off the Pink Sheets after its sole market maker at the time, The Vertical Group, follows Seaboard in ditching the lab. To whom it may concern, Please be advised that as of April 26, 2006 The Vertical Group has dropped making a market in LSRI. Sincerely, The Vertical Group.

COMPANIES THAT DROPPED HUNTINGDON IN 2005 - Nucryst Pharmaceutical, Johnson and Johnson, Santen, Accent Hansen, Algar, Signcraft, Allport, Archer, Ashtead Plant Hire, Bedfordshire Growers, Brett Martin, British Gypsum, BSS, Bulk Gas, Cambridge Courier Services, Cambridge Plant and Demolition Ltd, Caterfix, CCS Landhaul, Chiltern, Chubb Concrete Company, Cross Country Carriers, Danish Bakery, Data Sciences, David Ball Group, Den Caney Coaches, DG Freight, Dickerson Group, Durapipe, DW Clark, ECR, First Choice Coffee, First Flight Forwarders, Flex-Able Travel, Front Row, Gemmix Ltd, Hamilton Rentals, Hankyu, Hartrodt, Healthcare Logistics, Heathrow Import Clearance, Hewden, Hexagon, House of James, HQ Forklifts, HSS, Huntingdon Plant Hire, Initial City Link, Innaphase, Ipswich Plastics, J Watson Scaffolding, James Latham, JCH Laundry, Johnstones Leyland Decorating Centre, Knights of Old, Labtronics, Laminar Medica, Leapfrog Day Nurseries, Lynn Star, Matthews Transport, MC Freeze, Medifacts, MFI, Network Services, Night Freight, North Yorkshire Timber, Pall-Ex, Planet Same Day Couriers, Plastic Pipe Supplies, Prestons of Potto, Ray Harvey Fish Merchants, RJ Warren, RJJ Worldwide, Scarlet Couriers, SDV, Seko, Simonds Coach and Travel, Smiths Medical, Souters Transport, Speedy Hire, Stan Robinson, Star Transport, Suttons, Trio, United Pallet Network, Vet Diagnostics, Vindon, Whittle Painting, Windsor Engineering, World Precision Instruments, Douglas Brass, Sanderson Transport, D & G Noble, Awad, Cortina, Domestic Securities, Greenville Capital, Management, Inc., Royce, Thomson, UBS Global Capital Markets, Vertical Group, Washington Mutual

direct send
sample letter

go to petition instead

how to email a letter:

Copy LETTER below. Paste into an email.
Change some words. Sign name, address, country.
Copy EMAIL ADDRESSES. Paste in TO: line of an email. SEND letter from your email program.

how to fax or mail a letter:

Open sample letter as a DOC or PDF.
Change some words. Sign name, address, country.
Print letter to fax or mail using CONTACT INFORMATION on this page or in the DOC or PDF.

THIS ALERT IS CLOSED.
CLICK HERE FOR NEW ALERT: TARGET ASTRAZENECA - H.L.S CUSTOMER, BEAGLE KILLER

Dear Sir/Madam,

I am concerned about the welfare of animals used in the development of your products. I understand that both AstraZeneca and GlaxoSmithKline severed ties with Huntingdon_Life_Sciences (H.L.S) after an investigation exposed routine animal abuse inside the research facility.

Your good faith in Huntingdon’s promise to clean up its act led you to renew your contract. Sadly, abuse remains the norm at H.L.S. As recently as 2008, a published report about primate trafficking across South America and Asia described wild-caught monkeys squashed in cages for 30-hour treks to Huntingdon-Life-Sciences in Cambridgeshire.

Inside the primate unit, an undercover worker saw restrained monkeys forcibly overdosed on test materials via tube or inhalation. He recorded animals in filthy cages who went crazy, gnawing fingers and toes to the bone. One primate was tube fed after self-inflicted wounds left her face in shreds. The investigator counted 217 monkeys killed in just five studies for customers such as GlaxoSmithKline and AstraZeneca.

I respectfully ask you to rejoin the global list of customers, suppliers and financiers who dropped HLS after learning about the lab’s habitual abuse, falsification of test data, sloppy protocol, and employee misconduct.

Evidence from seven investigations over 12 years has exposed Huntingdon for multiple breaches of the U.S. Animal Welfare Act, the arrest of workers on animal cruelty charges, more than 520 infringements of Good Laboratory Practice in England, and a $50,000 payoff to the U.S. Agriculture Department for misstated records and animal welfare violations.

In 2005, two former H..LS workers testified that animals were insufficiently anesthetized before invasive procedures, such as painful extraction of bone marrow from the chest bone. Workers transferred blood into the wrong tubes. One "would go in and out about five times with the same needle, not hitting the vein," the past employee maintained. "I saw co-workers grab [dogs] by the scruff, shout and swear at them, swing them by the scruff and slap them."

Many labs now meet testing criterion with non-animal methods that yield data more relevant to human health and safety. H.L.S, on the other hand, abuses animals for invalid and redundant experiments.

I urge you to permanently terminate all business with Huntingdon-Life-Sciences. Thank you for your valuable time and consideration.

Thank you,

YOUR FULL NAME
ADDRESS, CITY, STATE
COUNTRY

contact information

go to petition instead

Most alerts have many email recipients. If one or more emails bounce that does NOT mean all failed.

Send failed email messages to: info@kinshipcircle.org Please do not send us hostile notes.

Official websites list outdated or incorrect emails.
Recipients block emails if swamped with mail.
A server may be down or not accepting email.
The email recipient's inbox is full (over quota).
Occasionally the same email works at later time.

full contact information

THIS ALERT IS CLOSED.

ASTRAZENECA
CONTACT INFORMATION - FROM 2012-2013 DOCUMENTS
PRIMARY SOURCES:
- AstraZeneca PLC, UK, 2012 (AstraZeneca plc.pdf)
- 2012 Red Books LLC, AstraZeneca Pulbic Limited Co.
- View Source: 2012 Red Books LLC, AstraZeneca
- AstraZeneca 2013 Executive Leaders

AstraZeneca Senior Executive Team

Simon Lowth, Executive Director & Chief Financial Officer: simon.lowth@astrazeneca.com
David Smith, Executive Vice President, Global Operations & Information Services: david.smith@astrazeneca.com
Katarina Ageborg, Chief Compliance Officer: katarina.ageborg@astrazeneca.com
Lynn Tetrault Executive Vice President, Human Resources & Corporate Affairs: lynn.tetrault@astrazeneca.com
Jeff Pott, General Counsel: jeffrey.pott@astrazeneca.com

7 Senior Executive emails below are configured in AstraZeneca�s format. There is no confirmed evidence that any are real addresses. These emails may bounce.

Pascal Soriot, Executive Director & Chief Executive Officer: pascal.soriot@astrazeneca.com
Mene Pangalos, Executive Vice President, Innovative Medicines: Mene.Pangalos@astrazeneca.com
Bahija Jallal, Executive Vice President, MedImmune: Bahija.Jallal@astrazeneca.com
Briggs Morrison, Executive Vice President, Global Medicines Development: Briggs.Morrison@astrazeneca.com
Paul Hudson, Executive Vice President, North America: Paul.Hudson@astrazeneca.com
Ruud Dobber, Executive Vice President, Europe: Ruud.Dobber@astrazeneca.com
Mark Mallon, Executive Vice President, International: Mark.Mallon@astrazeneca.com

AstraZeneca PLC
2 Kingdom Street
Paddington
London W2 6BD
United Kingdom
corporate phone: +44-20-7304-5000
44 20 7604 8000; fax: 44 20 7604 8151
Investor Relations: IR@astrazeneca.com
website: www.astrazeneca.com

Amy Allen, Manager, Clinical Research: amy.allen@astrazeneca.com
Genevieve Berger, Non-Executive Director, Member of the Science Committee
Colin Bergstrand, Director, Programs: colin.bergstrand@astrazeneca.com, +44-7920-587-712
Michael Boas Manager, Global Brand: michael.boas@astrazeneca.com
Neil Broster, Manager, IS Quality & Test: neil.c.broster@astrazeneca.com
Daniel Brown, Manager, Formulation Development: daniel.brown@astrazeneca.com
Bruce Burlington, Non-Executive Director & Member, Science Committee: bruce.burlington@astrazeneca.com
Graham Chipchase, Non-Executive Director & Member, Audit Committee
Jared Cohen, Manager, Marketing Manager: jared.cohen@astrazeneca.com
Charles Cottman, Project Coordinator: charles.cottman@astrazeneca.com
Jean-Philippe Courtois, Non-Executive Director & Member, Audit Committee: jean-philippe.courtois@astrazeneca.com
Charlotte Cousins, Administrative Coordinator, Purchasing: charlotte.cousins@astrazeneca.com
Samantha Covell, Head, Information Systems Procurement
Assunta Cuccia, Study Delivery Team Leader: assunta.cuccia@astrazeneca.com
Polina Denisenko, Mgr, PR, Russia: polina.denisenko@astrazeneca.com
Vikram Dev, Project Manager: vikram.dev@astrazeneca.com
Jim Dolceamore, Manager, Lab Engineering: jim.dolceamore@astrazeneca.com
Mike Eastgate, Manager, IT Services: mike.eastgate@astrazeneca.com
Karen Edwards, Director, Global Portfolio, Digital: karen.edwards@astrazeneca.com, +44- 7780-956-187
Esra Erkal-Paler, Head, Global Media Relations
Karl Hard, Director, Investor Relations, UK Director: karl.hard@astrazeneca.com, +44-207-604-8124
Kim Harrington, HCP Brand Leader: kim.harrington@astrazeneca.com
Philip Hayes, Category Leader, Contract Management: philip.hayes@astrazeneca.com
Caroline Hempstead, VP, Corp Affairs, Global: caroline.hempstead@astrazeneca.com

Sarah Hemingway, International Marketing Coordinator: sarah.hemingway@astrazeneca.com
Jonathan Hunt, VP & Head, IR: jonathan.hunt@astrazeneca.com
Prashaant Huria, Head, Regional Information Systems, CEEMEA: prashaant.huria@astrazeneca.com
Leif Johansson, Non-Executive Chairman, Nomination and Governance Committee: leif.johansson@astrazeneca.com
Adrian Kemp, Company Secretary: adrian.kemp@astrazeneca.com
Sarah Lindgreen, Associate, Global Media Relations: sarah.lindgreen@astrazeneca.com
Jan Lundberg, Executive Vice President, Discovery Research: jan.lundberg@astrazeneca.com
Ellen Madford, Manager, Sourcing: ellen.madford@astrazeneca.com
Mats Marfalt, Project Manager: mats.marfalt@astrazeneca.com
Rudy Markham, Non-Executive Director & Chairman, Audit Committee: rudy.markham@astrazeneca.com
Sonia Matadial, Associate Clinical Project Manager: sonia.matadial@astrazeneca.com
Neil McCrae, VP, Corp Comm Grp: neil.mccrae@astrazeneca.com
David Morgan, Head, Information Systems: david.morgan@astrazeneca.com
Brian Morris, Manager, IS Quality: brian.morris@astrazeneca.com
Ken Morris, Vice President, IT Sourcing Strategy: ken.morris@astrazeneca.com
Bo Norden, Team Leader: bo.norden@astrazeneca.com
Robert W. Perkins, VP, Pub Policy & Promotional Affairs: robert.perkins@astrazeneca.com
Plamen Petrov, Principal Scientist: plamen.petrov@astrazeneca.com
Iain Rankin, Head, Information Management Delivery Centre, Stockport, UK: iain.rankin@astrazeneca.com
Carl Richards, Director, Information Systems, Global: carl.richards@astrazeneca.com
Dame Nancy Rothwell, Non-Executive Director & Chairman, Science Committee: nancy.rothwell@astrazeneca.com
Hitesh Sanganee, Team Leader: hitesh.sanganee@astrazeneca.com
Leslie Schaefer, Brand Leader: leslie.schaefer@astrazeneca.com
Adin Spring, Project Manager: adin.spring@astrazeneca.com
Eileen Stowe, Manager, Occupational Health: eileen.stowe@astrazeneca.com
Fred Taylor, Project Manager: fred.taylor@astrazeneca.com
John Tyson, Project Manager, Information Technology: john.tyson@astrazeneca.com
Annmarie Ungaro, Project Manager: annmarie.ungaro@astrazeneca.com
Baroness Vadera, Non-Executive Director & Member, Audit Committee: shriti.vadera@astrazeneca.com
John Varley, Senior Non-Executive Director & Chairman, Remuneration: john.varley@astrazeneca.com
Marcus Wallenberg, Non-Executive Director & Member, Science Committee: marcus.wallenberg@astrazeneca.com
James Ward-Lilley, Regional Vice President, UK:
+44-207-604-8122
Barbara Wenrich, Project Coordinator: barbara.wenrich@astrazeneca.com
Nicklas Westerholm, Head, Global API Supply, UK: nicklas.westerholm@astrazeneca.com, +44-207-604-8123

AstraZeneca US
AstraZeneca PLC
1800 Concord Pike
P.O. Box 15437
Wilmington, DE 19850-5437 USA
corporate phone: +1-302-886-3000

Michael Ade, Project Manager, Enterprise IS: michael.ade@astrazeneca.com
Gary Csaniz, Senior Manager, Enterprise Data Architecture: gary.csaniz@astrazeneca.com
Julien Durand, Regional Compliance Officer & Ethical Innovation Lead, Latin America: julien.durand@astrazeneca.com
Rich Fante, President, US Business & Regional Vice President, Americas: rich.fante@astrazeneca.com
Johan Hoegstedt, Vice President, Managed Markets: johan.hoegstedt@astrazeneca.com

Rod Hoffman, Senior Manager, Business Information: rod.hoffman@astrazeneca.com
Deborah Kauffman, Vice President, Human Resources: deborah.kauffman@astrazeneca.com
Jonathan Kirby, Chief Information Officer: +44-20-7604-8185 or +44-20-7684- 8186
John McCarthy, Vice President, Commercial Operations
Marion McCourt, Chief Operating Officer: marion.mccourt@astrazeneca.com
Stephen Mohr, General Counsel, US & Regional Legal Director, Americas
Kathy Monday, Regional Vice President, Supply, Americas: kathy.monday@astrazeneca.com
David Nicoli, Vice President, Corporate Affairs: david.nicoli@astrazeneca.com
Linda Palczuk, Vice President, Sales & Marketing, Cornerstone: linda.palczuk@astrazeneca.com
Lisa Schoenberg, Vice President, Sales & Marketing, Growth: lisa.schoenberg@astrazeneca.com
Matt Talbot, Senior Manager, Information Services Business Analysis: matt.talbot@astrazeneca.com
Mark Uhle, Chief Financial Officer, US & Regional Finance Director, Americas
John Yee, Vice President & Head Medical Officer: john.yee@astrazeneca.com
Angela Yochem, Chief Technology Officer: angela.yochem@astrazeneca.com

AstraZeneca AB
AstraZeneca Nordic Headquarters
Karlebyhus, Astra Allen
SE-151 85 Soedertaelje
ph: +46-8-5532-6000
fax: +46 (0) 8 553 290 00
email: kontakt@astrazeneca.com
website: www.astrazeneca.se

Peter Alvarsson, Head, Operational Excellence:
+46-8-5525-4480
Torkel Arman, Specialist, SAP Master Data Specialist
Monica Axen, Director, Global Supply Director
Magnus Blomberg, Director, Global Project & Change: magnus.blomberg@astrazeneca.com, +46-8-5525-7952
Erik Briselius, Senior Solutions Architect Manager: erik.briselius@astrazeneca.com, +46-4-633-7616
Per Edvardsson, Associate Director, Manufacturing
Anders Ekblom, President, AstraZeneca AB
Erik Ekman, Europe ERP Sweden Lead
Joachim Fishman, Business Controller
Clas Furusten, Project Manager, Information Systems: clas.furusten@astrazeneca.com, +46-8- 5532-9029
David Fussell, Director, Supply & Manufacturing
Benny Hansen, Manager, Service Process Support: benny.hansen@astrazeneca.com, +46-8- 5532-4215
Osborn Harmestad, Manager, Strategy & Portfolio Manager Direct: osborn.harmestad@astrazeneca.com, +46-8-5525-5977
Goeran Hellstroem, Manager, Information Technology
Goeran Henrixon, Manager, Service Design & Introduction
Nisse Hoeglund, Business Controller
Eva Iden, Head, API Supply
Per Jardhagen, Business Controller
Pontus Kavestam, Business Controller
Lars Klinga, Manager, Infrastructure Commercial Control: lars.klinga@astrazeneca.com, +46-8- 5532-8772
Anki Knutar, Accountant
Tord Larfe, Project Manager, Information Systems: tord.larfe@astrazeneca.com, +46-8-5532-7308
Sofi von Laskowski, Finance Business Analyst
Kristian Lindberg, IS Security
Michael Linder, Manager, System
Jonny Lindstroem, Manager, Global
Elaine Marks, PMO Lead, Collaboration
Per Matsson, Analyst, Business Reporting & Analytics
Richard Nilsson, Senior Usability Architect
Michael Oehman, Manager, IT Infrastructure: michael.ohman@astrazeneca.com, +46-8-5532-6360
Staffan Palerius, Principal Programmer, R&D
Asa Ringstroem, Manager, Infrastructure Delivery, Enterprise Shared Services
Henk Schaake, Manager, Business System
Richard Sedin, Lead, Local Process Champion, Operations
Maria Ullbrand, PMO Lead
Anders Vikdahl, Head of Sweden Operations
Tomas Wahlgreen, Manager, Business Relationship, Maintenance & Document Management: tomas.wahlgreen@astrazeneca.com, +46-953-200-9196
Hanna Wallin, Manager, Senior Service

AstraZeneca R&D, Charnwood
+44-1509-644-000

Roland Bogush, Director, Clinical IT Business Engagement: roland.bogush@astrazeneca.com, +44- 1509-645-009 or
+44-7867-905-971
Peter Colman, Group Manager, Statistics & Programming: peter.colman@astrazeneca.com
Janet Edwards, Chief of Staff, Clinical Development: janet.edwards@astrazeneca.com
Lesley France, Director, Statistics & Programming Section: lesley.france@astrazeneca.com
Anne Galer, Senior Project Director, Innovative Medicines Oncology: anne.galer@astrazeneca.com
Margaret Gold, Manager, Global IS Quality & Compliance: margaret.gold@astrazeneca.com
Mark Howard Manager, Global IS Risk & Security: mark.howard@astrazeneca.com, +44-1509- 644-485
Andrew Hudson, Global Head, Patient Safety Systems & Information Strategy: andrew.hudson@astrazeneca.com
Amrik Mahal, Associate Director, Clinical: amrik.mahal@astrazeneca.com
Darren McKerrecher, Associate Director, Medicinal Chemistry: darren.mckerrecher@astrazeneca.com

Stephen Partridge, Global Director, Clinical Project Management: stephen.partridge@astrazeneca.com
Gopal Sharma, Senior Manager, Strategy: gopal.sharma@astrazeneca.com
Mike Snowden, Vice President, Discovery Sciences: mike.snowden@astrazeneca.com, +44- 1625-517-077
Kevin Teburi, Associate Project Director & Service Delivery Leader: kevin.teburi@astrazeneca.com
Maria-Elena Theoclitou, Group Manager, Clinical Development & Leader, Study Operations Programme: mariaelena.theoclitou@astrazeneca .com
Mark Weaver, Global Head, Archives & Records Management, AstraZeneca R&D, Charnwood: mark.weaver@astrazeneca.com
Peter Webborn, Director, Global Pharmacokinetics: peter.webborn@astrazeneca.com

AstraZeneca Czech Republic, s.r.o.

Katerina Honajzerova, Sales & Marketing Coordinator, Cardiovascular & Diabetology: +420-2-2280-7111
Josef Vaclavik, Manager, Information Technology: josef.vaclavik@astrazeneca.com, +420-2-2280-7126
Robert Weigl, President, AstraZeneca Czech Republic: robert.weigl@astrazeneca.com, +420-2- 2280-7210

GLAXOSMITHKLINE
SOURCE: info@shac.net

Andrew Witty, CEO, Board of Directors, Andrew.Witty@gsk.com
Julian Heslop, Chief Financial Officer, Board of Directors, Julian.Heslop@gsk.com
Moncef Slaoui, Chairman of Research-Development, Board of Directors, Moncef.Slaoui@gsk.com
David Pulman, President of Global Manufacturing and Supply, David.Pulman@gsk.com
Marc Dunoyer, President of Asia Pacific-Japan, Marc.Dunoyer@gsk.com
President of North American Pharmaceuticals, Board of Directors, Chris.Viehbacher@gsk.com
John Clarke, President of Consumer Healthcare, John.Clarke@gsk.com
Simon Bicknell, SVP, Company Secretary and Compliance Officer, Simon.M.Bicknell@gsk.com
Dan Phelan, Chief of Staff, Daniel.Phelan@gsk.com
Claire Thomas, SVP, Human Resources, Claire.x.Thomas@gsk.com

GLAXOSMITHKLINE WORLDWIDE ADDRESSES
SOURCE: www.gsk.com/worldwide.htm
GlaxoSmithKline U.S. Corporate Headquarters
5 Moore Drive
Research Triangle Park, NC 27709
US corporate switchboard: 1 888-825-5249
US Customer Response Center: 1 888-825-5249

Glaxo Wellcome UK Ltd.
Stockley Park West, Uxbridge
Middlesex, UB11 1BT
ph: 020 8990 9000, 0800 221441
fax: 020 8990 4321, 020 8990 4328

automated web petition

go back to direct-send

about web petitions
When you use the web petition instead of direct-send, your comments — and everyone else's — come from one place: Our website server.

WEB PETITIONS REQUIRE THE LEAST EFFORT, BUT SOMETIMES CAN:

Create a spam effect that angers recipients and hurts outcome for animals.
Compel recipients to block the entire petition, so no one's comments get through.

Your tax-deductible gift pays to develop learning initiatives and mass print literature for educators, advocates, students… Together, we can spread the truth about animals!

source of information & references

ORIGINAL ALERT SOURCES: Due to government suppression of activists associated with HLS protests, some links may no longer work. HLS Top Targets ADI report and 2008 video footage shot inside HLS Save The Primates, Documentary from ADI and NAVS HUNTINGDON LIFE SCIENCES EXPOSED All Global HLS Targets Campaign to close Huntingdon Life Sciences
DISCLAIMER: Information in these materials is verified with original source. Kinship Circle does not assume responsibility for accuracy of information or for consequences of its use. Nothing on this website intends to encourage illegal action in whatever country you are reading it in. Kinship Circle does not engage in, nor support, any form of harassment or unlawful action. Nothing in this alert serves to promote such conduct. EMAIL ADDRESSES: Kinship Circle cannot guarantee validity of email addresses. During a campaign, recipients may change or disable their email addresses. Email addresses obtained from government or other official websites may be outdated or incorrect.

KINSHIP CIRCLE
Animal Advocacy  |  Education  |  Disaster Aid

info@kinshipcircle.org  •  KinshipCircle.org  •  KinshipCircle.org/disasters
314-795-2646  |  7380 Kingsbury Blvd  |  Saint Louis, MO 63130 USA

Kinship Circle is a nonprofit focused in: Animal Cruelty Investigation & Action, Humane Education, and Disaster Animal Response.
●  Federal 501c3 under U.S. IRS ruling, Public Charity Status: 170b1Avi
●  Tax Employee Identification Number (EIN) available upon request
●  Nonprofit Certificate of Incorporation, Charter: N00071626
●  PRIVACY POLICY